CAMXApproval•prnewswire•
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
Sentiment:Positive (70)
Summary
LUND, Sweden, Aug. 28, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa®, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 28, 2025 by prnewswire